Troponin is a useful marker in clinical decision making in hospitalized patients with COVID-19 infections
نویسندگان
1 Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran
2 Assistant Professor, Gastrointestinal and Liver Diseases Research Center AND Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
3 Associate Professor, Department of Pulmonology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran
4 Assistant Professor, Department of Internal Medicine, School of Medicine, Firoozgar General Hospital, Iran University of Medical Sciences, Tehran, Iran
5 Resident, Department of Internal Medicine, School of Medicine, Firoozgar General Hospital, Iran University of Medical Sciences, Tehran, Iran
6 Associate Professor, Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran
7 Associate Professor, Department of Interventional Radiology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran
8 Assistant Professor, Department of Cardiology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran
9 Assistant Professor, Department of Cardiology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran
10 Professor, Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran
11 Assistant Professor, Department of Internal Medicine, School of Medicine, Firoozgar General Hospital, Iran University of Medical Sciences, Tehran, Iran
12 Associate Professor, Department of Social Medicine, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
13 Assistant Professor, School of Science, Engineering and Computing, Kingston University, Kingston, United Kingdom
14 Assistant Professor, Department of Pulmonology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran
15 Professor, Department of Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran
16 Assistant Professor, Department of Hematology and Medical Oncology, School of Medicine, Iran University Medical Sciences, Tehran, Iran
17 Associate Professor, Research Center for Prevention of Cardiovascular Disease, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran
18 Assistant Professor, Department of Cardiology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran
19 Assistant Professor, Department of Pathology, Iran University of Medical Sciences, Tehran, Iran
20 Assistant Professor, Department of Pathology, Iran University of Medical Sciences, Tehran, Iran
doi
10.22122/arya.v17i0.2191چکیده
BACKGROUND: COVID-19 was introduced by the World Health Organization (WHO) as a global pandemic. The spectrum of symptoms of the disease ranges from a mild cold to death. It has a higher mortality rate in people with a history of comorbidities, including cardiovascular disease (CVD) and can also contribute to cardiac injury. This study was conducted to evaluate the relationship between troponin levels as a cardiac marker and adverse outcomes in this disease.METHODS: The study sample included 438 patients hospitalized with COVID-19; however, the troponin data of 6 patients were not available. The need to be admitted to the intensive care unit (ICU), and death were considered the adverse outcome in patients with COVID-19. Troponin levels were checked in all patients on day 1 and day 3 of hospitalization. Multiple logistic regression analysis was performed to determine whether there was an independent association between the adverse outcomes and troponin enzyme in hospitalized patients with COVID-19.RESULTS: The mean age of patients was 61.29 ± 15.84 years. Among the 432 patients tested on day 1 of hospitalization, 24 patients (5.6%) tested positive (Troponin 1), and among the 303 patients tested on day 3, 13 patients (4.3%) tested positive (Troponin 2). Based on our results, Troponin 1 showed an independent association with both death (3.008 [95%CI = 1.091-8.290]; P = 0.033) and need for ICU admission (8.499 [95%CI = 3.316-21.788]; P < 0.001) in multiple logistic regression analysis. Moreover, the status of Troponin 2 had an independent significant association with both death (4.159 [95%CI = 1.156-14.961]; P = 0.029) and ICU admission (7.796 [95%CI = 1.954-31.097]; P = 0.004).CONCLUSION: Troponin showed a significant association with adverse outcomes in people who were hospitalized with COVID-19. The serial assessment of this enzyme from the time of hospitalization may improve the clinical decision making of clinicians.
